ArticlePLOS global public health2026
Leveraging current capacity to address the high prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in South Africa: Modelling potential costs and benefits of near point-of-care GeneXpert testing for STIs.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cost-effectiveness and cost-utility of antenatal sexually transmitted infection screening to reduce preterm birth and low birthweight in South Africa.medRxiv : the preprint server for health sciences · 2026Article
- Impact of antenatal screening for Chlamydia and Gonorrhea on pregnancy outcomes in South African women.BMC infectious diseases · 2026Article
- Point-of-care testing to strengthen sexually transmitted infection case management in resource-constrained settings.Sexually transmitted infections · 2026Article
- STI prevalence and the integration of point-of-care nucleic acid amplification testing into STI diagnostic algorithms at a Médecins Sans Frontières key population clinic in San Pedro Sula, Honduras.Frontiers in reproductive health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
South Africa has high sexually transmitted infections (STIs) prevalence and currently implements syndromic management, which has limitations including untreated asymptomatic infections and excess antibiotic use. Diagnostic tools like GeneXpert may offer potential improvements. We evaluated potential costs and benefits of GeneXpert for STIs testing. We developed a static analytical model using existing data over a one-year time horizon (January-December 2024) from a provider perspective. We estimated costs (2024 USD), outcomes, cost-effectiveness, and budget impact of syndromic management and multiple near point-of-care (i.e., off-site laboratory) GeneXpert testing scenarios for Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis. Target groups included symptomatic individuals, antenatal care (ANC) attendees, and HIV testers. Deterministic sensitivity analysis was conducted on key parameters. Cost per person, and per person correctly diagnosed and treated ranged from $21-$29 under syndromic management and $88-$755 in GeneXpert scenarios. Syndromic management cost the healthcare system an estimated $24.1 million per year; symptomatic GeneXpert testing would cost substantially more: $102.1-$207.8 million, and $300.9 million-$2.1 billion for GeneXpert scenarios involving symptomatic individuals, ANC attendees, and HIV testers. GeneXpert testing reduces excess antibiotic use by up to 88% compared to syndromic management. Of scenarios modelled, three were on the cost-effectiveness frontier: syndromic management, S4: symptomatic adults and adolescent girls and young women HIV testers, and S8: symptomatic adults, ANC attendees and HIV testers. While syndromic management was least costly, incremental cost per additional person correctly diagnosed and treated was $863 (S4) and $1,064 (S8). These scenarios would cost $3.5 and $12.0 billion over 5-years, respectively, compared to $146.0 million in syndromic management. Staff and diagnostic cost were the most influential parameter in sensitivity analysis. Prioritizing GeneXpert testing for symptomatic individuals and high-risk groups (e.g., HIV testers) can improve STI management but requires additional investment. These findings support the need for targeted strategies to optimise STI control.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.